Jyong Biotech Ltd. Ordinary Shares (MENS) Stock Ticker
MENS right now
Market factors today
Unlock the full MENS picture
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
MENS stock facts
| Ticker symbol | MENS |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $149.8M |
| CEO | Fu-Feng Kuo |
| Employees | 27 |
| Headquarters | New Taipei City, TP, TW |
| IPO date | 2025-06-17 |
| Website | www.jyongbio.com |
What you can see for MENS on Tickr
Live MENS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the MENS report.
Rankings
FAQ
What is the ticker symbol for Jyong Biotech Ltd. Ordinary Shares?
The ticker symbol for Jyong Biotech Ltd. Ordinary Shares is MENS, listed on the NASDAQ Global Select.
What is MENS?
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug…